Combination of Ad-SGE-REIC and bevacizumab modulates glioma progression by suppressing tumor invasion and angiogenesis

Reduced expression in immortalized cells/Dickkopf-3 (REIC/Dkk-3) is a tumor suppressor and its overexpression has been shown to exert anti-tumor effects as a therapeutic target gene in many human cancers. Recently, we demonstrated the anti-glioma effects of an adenoviral vector carrying REIC/Dkk-3 with the super gene expression system (Ad-SGE-REIC). Anti-vascular endothelial growth factor treatments such as bevacizumab have demonstrated convincing therapeutic advantage in patients with glioblastoma. However, bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma. In this study, we examined the effects of Ad-SGE-REIC on glioma treated with bevacizumab. Ad-SGE-REIC treatment resulted in a significant reduction in the number of invasion cells treated with bevacizumab. Western blot analyses revealed the increased expression of several endoplasmic reticulum stress markers in cells treated with both bevacizumab and Ad-SGE-REIC, as well as decreased β-catenin protein levels. In malignant glioma mouse models, overall survival was extended in the combination therapy group. These results suggest that the combination therapy of Ad-SGE-REIC and bevacizumab exerts anti-glioma effects by suppressing the angiogenesis and invasion of tumors. Combined Ad-SGE-REIC and bevacizumab might be a promising strategy for the treatment of malignant glioma.

[1]  S. Bicciato,et al.  Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in Glioblastoma , 2020, Nature Cancer.

[2]  T. Hishikawa,et al.  Study protocol of a Phase I/IIa clinical trial of Ad-SGE-REIC for treatment of recurrent malignant glioma. , 2020, Future oncology.

[3]  I. Nakano,et al.  Current approaches and challenges in the molecular therapeutic targeting of glioblastoma. , 2019, World neurosurgery.

[4]  I. Date,et al.  Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways , 2019, Molecular Cancer Therapeutics.

[5]  I. Date,et al.  δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion , 2019, Molecular Cancer Therapeutics.

[6]  Lu He,et al.  Wnt/β‐catenin signaling cascade: A promising target for glioma therapy , 2018, Journal of cellular physiology.

[7]  Y. Matsumoto,et al.  Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion , 2018, Oncogene.

[8]  K. Ligon,et al.  Glioblastoma targeted therapy: updated approaches from recent biological insights , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  F. Nicoletti,et al.  Dickkopf-3 Upregulates VEGF in Cultured Human Endothelial Cells by Activating Activin Receptor-Like Kinase 1 (ALK1) Pathway , 2017, Front. Pharmacol..

[10]  Masami Watanabe,et al.  Adenovirus vector carrying REIC/DKK-3 gene: neoadjuvant intraprostatic injection for high-risk localized prostate cancer undergoing radical prostatectomy , 2016, Cancer Gene Therapy.

[11]  M. Sakaguchi,et al.  A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy , 2016, Scientific Reports.

[12]  K. Shirahige,et al.  DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation , 2016, Nature Communications.

[13]  H. Prats,et al.  Glioblastoma invasion and cooption depend on IRE1α endoribonuclease activity , 2015, Oncotarget.

[14]  S. Kanazawa,et al.  Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy , 2015, Clinical Medicine Insights. Oncology.

[15]  K. Fujii,et al.  Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma , 2014, Gene Therapy.

[16]  V. Perrot,et al.  Direct Effect of Bevacizumab on Glioblastoma Cell Lines In Vitro , 2014, NeuroMolecular Medicine.

[17]  I. Date,et al.  Integrin Inhibitor Suppresses Bevacizumab-Induced Glioma Invasion12 , 2014, Translational oncology.

[18]  P. He,et al.  Rsf-1 overexpression in human prostate cancer, implication as a prognostic marker , 2014, Tumor Biology.

[19]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[20]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[21]  M. Sakaguchi,et al.  A novel gene expression system strongly enhances the anticancer effects of a REIC/Dkk-3-encoding adenoviral vector , 2013, Oncology reports.

[22]  E. Chiocca,et al.  Gene expression profiling of the anti-glioma effect of Cilengitide , 2013, SpringerPlus.

[23]  I. Date,et al.  Bimodal anti‐glioma mechanisms of cilengitide demonstrated by novel invasive glioma models , 2013, Neuropathology : official journal of the Japanese Society of Neuropathology.

[24]  J. Heymach,et al.  Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. , 2012, Neuro-oncology.

[25]  F. Saltel,et al.  Autocrine control of glioma cells adhesion and migration through IRE1&agr;-mediated cleavage of SPARC mRNA , 2012, Journal of Cell Science.

[26]  Konrad Basler,et al.  The many faces and functions of β‐catenin , 2012, The EMBO journal.

[27]  Tao Chen,et al.  Notch1 promotes glioma cell migration and invasion by stimulating β‐catenin and NF‐κB signaling via AKT activation , 2012, Cancer science.

[28]  Stephen Yip,et al.  Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. , 2012, Neuro-oncology.

[29]  G. Fuller,et al.  Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice , 2010, Neuro-oncology.

[30]  Khalid Shah,et al.  Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. , 2009, Cancer research.

[31]  M. Sakaguchi,et al.  Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis. , 2008, Cancer research.

[32]  D. Blumenthal,et al.  Treatment with bevacizumab and irinotecan for recurrent high‐grade glial tumors , 2008, Cancer.

[33]  M. Hermann,et al.  The Dickkopf‐homolog 3 is expressed in tumor endothelial cells and supports capillary formation , 2007, International journal of cancer.

[34]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Kaufman,et al.  Autocrine Tumor Necrosis Factor Alpha Links Endoplasmic Reticulum Stress to the Membrane Death Receptor Pathway through IRE1α-Mediated NF-κB Activation and Down-Regulation of TRAF2 Expression , 2006, Molecular and Cellular Biology.

[36]  M. Sakaguchi,et al.  Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase. , 2005, Cancer research.

[37]  H. Okano,et al.  An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. , 2005, Cancer research.

[38]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[39]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Sakaguchi,et al.  Antiproliferative activity of REIC/Dkk-3 and its significant down-regulation in non-small-cell lung carcinomas. , 2001, Biochemical and biophysical research communications.

[41]  M. Sakaguchi,et al.  A REIC gene shows down-regulation in human immortalized cells and human tumor-derived cell lines. , 2000, Biochemical and biophysical research communications.

[42]  H. Shiraha,et al.  A Phase I/Ib trial of Ad-REIC in liver cancer: study protocol. , 2019, Future oncology.

[43]  I. Date,et al.  Cilengitide treatment for malignant glioma: current status and future direction. , 2012, Neurologia medico-chirurgica.